Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.

Yuka Kawaji-KanayamaTsutomu KobayashiAyako MuramatsuHitoji UchiyamaNana SasakiNobuhiko UoshimaMitsushige NakaoRyoichi TakahashiKazuho ShimuraHiroto KanekoMiki KiyotaKatsuya WadaYoshiaki ChinenKoichi HirakawaShin-Ichi FuchidaChihiro ShimazakiYayoi Matsumura-KimotoShinsuke MizutaniTaku TsukamotoYuji ShimuraShigeo HoriikeMasafumi TaniwakiJunya Kurodanull null

Published in: Cancer reports (Hoboken, N.J.) (2021)

This study suggests the need of the development of novel CFZ-containing strategy which can overcome the refractoriness to BTZ and/or LEN, while both KRD and KD were shown to be mostly feasible in Asian patients in a daily practice setting.

Keyphrases

multiple myeloma
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
peritoneal dialysis
healthcare
primary care
acute myeloid leukemia
clinical trial
physical activity
acute lymphoblastic leukemia
randomized controlled trial
patient reported outcomes
double blind